The team did note that paravalvular leakage was seen in a small number of patients, but the team found no evidence of structural valve deterioration. Bleeding events, meanwhile, remain a complication clinicians must keep an eye on at all times.
“The incidence of major, extensive, life-threatening or fatal bleeding in this study was not trivial,” wrote lead author David W.M. Muller, MBBS, MD, a cardiologist at St. Vincent’s Hospital in Sydney, Australia, and colleagues. “Bleeding in the first three months was predominantly procedural but thereafter included intracranial and gastrointestinal bleeding, events more likely to occur in the presence of long-term oral anticoagulation. Although the study protocol did not mandate anticoagulation beyond three months postprocedurally, the majority of survivors (84.0%) remained anticoagulated at two-year follow-up.”
Overall, however, these two-year findings suggest that TMVR provides significant value for patients presenting with severe MR.
“The elimination of MR and improvements in functional status and quality-of-life measures noted at one year were sustained to two years,” the authors concluded. “Ongoing clinical studies will help define the patient cohorts most likely to benefit from this novel therapy.”
Read the full study here.
"severe" - Google News
November 03, 2021 at 03:39AM
https://ift.tt/3q6saxb
Two-year outcomes highlight the value of TMVR for patients with severe MR - Cardiovascular Business
"severe" - Google News
https://ift.tt/2OrY17E
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
Bagikan Berita Ini
0 Response to "Two-year outcomes highlight the value of TMVR for patients with severe MR - Cardiovascular Business"
Post a Comment